Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Lancet Infectious Diseases
Oct 2021 Volume 21 Number 10 p1333-1470, e302-e340
https://www.thelancet.com/journals/laninf/issue/current

 

Articles
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Keith J Chappell, et al.